EGFR and neoplasm: However, despite important responses in previously intractable cases, first‐generation (e.g., gefitinib and erlotinib) and second‐generation (e.g., dacomitinib and afatinib) EGFR‐TKIs provide in most instances only a few additional months of tumor‐free survival because of rapid development of resistance.